(Q37980202)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22292707%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

title

Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22292707%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22292707%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

Constantin A Dasanu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22292707%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Shounak Majumder

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22292707%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Elena Stoica-Mustafa

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22292707%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Guru Trikudanathan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22292707%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

language of work or name

English

0 references

publication date

1 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22292707%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

21 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22292707%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22292707%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22292707%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

461-471

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22292707%20AND%20SRC:MED&resulttype=core&format=json

Siegfried oberndorfer and the evolution of carcinoid disease

21 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

A 5-decade analysis of 13,715 carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Medical management of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Therapeutic options for gastrointestinal carcinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Sporadically occurring functional pancreatic endocrine tumors: review of recent literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

The management of insulinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

The usefulness of super-selective computed tomography angiography (CTA) for diagnosing and localizing a small insulinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Somatostatin and its receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

The pathophysiological consequences of somatostatin receptor internalization and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Peptide-receptor radionuclide therapy for endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Neuroendocrine tumors. Peptide receptor radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Clinical and in vitro studies of imatinib in advanced carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Influence of gynecologic oncologists on the survival of patients with endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.656089

10.1517/14656566.2012.656089

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22292707%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference